Background-Uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation is associated with a lower risk of periprocedural complications than when warfarin is temporarily discontinued. However, the optimal international normalized ratio (INR) levels during RFA have not been defined. Methods and Results-In this retrospective analysis, RFA was performed in 1133 consecutive patients (mean age, 61±10 years) with paroxysmal (550) or persistent atrial fibrillation (583). Patients were grouped based on the INR on the day of RFA. There was a quadratic relationship between the INR and bleeding and vascular complications (P<0.001). Complications were less prevalent when INR was ≥2.0 and ≤3.0 (5% [31/572]) than when INR was <2.0 (10% [49/485]; P=0.004) and >3.0 (12% [9/76]; P=0.03). The prevalence of pericardial tamponade (1%) was similar at all INRs. From the quadratic model, the optimal range of INR was calculated as 2.1 to 2.5. INRs<2.0 and >3.0 were associated with a >2-fold increase in complications, with a further steep rise beyond an INR>3.5. Concomitant clopidogrel use was associated with a significant increase in complications at all INRs (odds ratio=3.1; ±95% confidence interval, 1.4-7.4). Unfractionated heparin requirements to maintain a therapeutic activated clotting time during RFA was reduced by 50% in patients with an INR>2.0. Conclusions-The optimal INR range during uninterrupted periprocedural anticoagulation using warfarin is narrow. Therefore, INR levels should be carefully monitored in preparation for RFA of atrial fibrillation. (Circ Arrhythm Electrophysiol. 2013;6:302-309.)
R ecent studies have demonstrated that uninterrupted therapeutic anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation (AF) is associated with a lower risk of thromboembolic and bleeding complications compared with interrupted warfarin and bridging with fractionated and unfractionated heparin. [1] [2] [3] [4] However, the optimal range of international normalized ratios (INRs) has not been well defined. The purpose of this study was to determine the relationship between INR and the risk of thromboembolic and bleeding complications in patients undergoing RFA of AF.
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Methods
Study Subjects
The subjects of this study were 1133 consecutive patients who underwent RFA to eliminate AF with uninterrupted anticoagulation using warfarin between January 2010 and December 2011. There were 832 men and 301 women. The mean age was 61±10 years. AF was paroxysmal in 550 patients and persistent in 583 patients. The mean left atrial size and left ventricular ejection fraction were 44±7 mm and 0.56±0.11, respectively. The clinical characteristics of patients are shown in Table 1 .
Anticoagulation Protocol
All patients were scheduled to undergo RFA of AF without discontinuing warfarin. Warfarin therapy was started ≥4 weeks before the procedure with an INR goal of 2.0 to 3.0. A transesophageal echocardiogram was performed in all patients who had persistent AF, a previous thromboembolic event or left atrial appendage thrombus, or who had been in AF for >48 hours without adequate anticoagulation before the procedure. The INR was measured within 60 minutes before the RFA procedure. Unfractionated heparin was administered as a bolus (50-100 U/kg) after the transeptal puncture and then continuously infused to maintain an activated clotting time (ACT) of 300 to 350 seconds. The sheaths were removed once the ACT returned to baseline values. In all patients, the regular maintenance dose of warfarin was continued. In patients with an INR≥2.0 on the day of the procedure, no additional heparin was administered after the procedure. In patients with an INR<2.0 on the day of the procedure, intravenous heparin was infused 3 hours after vascular hemostasis was achieved and maintained during an overnight hospital stay. If the INR was still <2.0, the morning after the procedure, the patient was discharged home on LMWH (0.5 mg/kg SC, BID) until the INR was ≥2.0. Anticoagulation with warfarin was continued for ≥3 months after the RFA.
Electrophysiological Study and RFA
All patients provided informed written consent. The procedures were performed in the fasting state under moderate or deep sedation using propofol, fentanyl sodium, and midazolam at the direction of an anesthesiologist. Among the 1133 patients, 505 patients (45%) presented in sinus rhythm and 628 patients (45%) presented in AF. Vascular access was obtained through a femoral vein using the modified Seldinger technique. A 7F short sheath, and 2 8.5F SL 0 sheaths (St. Jude Medical) were placed into the same vein. A steerable decapolar catheter (Biosense Webster, Diamond Bar, CA) was positioned in the coronary sinus for recording electrograms and atrial pacing. Bipolar electrograms were displayed and recorded at filter settings of 30 to 500 Hz (EPMed Systems, West Berlin, NJ). After the transeptal puncture, antral pulmonary vein isolation was performed in all patients with a 3-dimensional electroanatomical mapping system (Carto 3, Biosense Webster). All pulmonary veins were mapped with a circular deca-or duo-decapolar catheter (Lasso, Biosense Webster). Ablation of complex fractionated atrial electrograms or linear ablation was performed at the discretion of the operator. A 3.5mm, open-irrigation-tip catheter (Thermocool, Biosense Webster) was used for mapping and radiofrequency energy delivery at a power of 20 to 35 W, and a flow rate of 17 to 30 mL/min, and at a maximum temperature of 48˚C.
Postprocedural Management and Follow-up
All patients had electrocardiographic monitoring during an overnight hospital stay after the RFA. All patients were seen in an outpatient clinic 3 months after the procedure or sooner as necessary.
Long-term follow-up was performed by clinic visits or telephone and mail.
Study Protocol
The study protocol of this retrospective analysis was approved by the Institutional Review Board of the University of Michigan. With a perspective on clinic utility, patients were categorized a priori, based on the preprocedural INR as follows: INR<1.5, 1.5 to <2.0, 2.0 to ≤2.5, 2.5 to ≤3.0, 3.0 to ≤3.5, and >3.5. However, regression analysis was performed incorporating INR as a continuous variable to identify a predictive model.
Complications were analyzed in 4 categories: (1) major bleeding complications; (2) minor bleeding complications; (3) thromboembolic complications; and (4) other complications. Major bleeding complications were defined as the following: (1) pericardial tamponade that required percutaneous or surgical drainage and (2) vascular complications, such as arteriovenous fistula, pseudoaneurysm, or hematoma that required percutaneous/surgical intervention, rehospitalization, a longer hospital stay, or a blood transfusion. Minor bleeding complications were defined as groin hematoma or any bleeding that did not require an intervention or prolonged hospitalization, such as self-limited hematuria, or epistaxis. Groin hematoma was defined as a symptomatic swelling at the vascular access site with an obvious collection of blood. Thromboembolic complications included ischemic stroke, peripheral thromboembolic events, and deep vein thrombosis. Although not reported in this study, potential complications include pulmonary vein stenosis, atrioesophageal fistula, and phrenic nerve palsy.
Statistical Analysis
Continuous variables were expressed as mean±SD. Continuous variables were compared by 1-way ANOVA with post hoc analysis using Tukey honestly significant difference test. Kruskal-Wallis test was used for analysis of continuous variables that did not have equal variance (baseline ACT, mean and maximum ACT, and unfractionated heparin per body weight). Categorical variables were reported as Table 1 . The mean CHADS 2 scores were similar among all groups. Aspirin was used less frequently when the INR was >3.0 (26%) than ≥2.0 and ≤3.0 (38%) and <2.0 (43%; P=0.02). Clopidogrel use was similar at all INRs. There was no significant difference in plasma hemoglobin, hematocrit, and platelet counts ( Table 1 ). There were not any clinical or laboratory predictors of INR levels.
Results
Procedural INR Levels
INR Levels, Intraprocedural ACT, and Heparin Requirements
There was a direct correlation between INR and baseline ACT (r=0.64; P<0.001), mean ACT (r=0.44; P<0.001), and maximum ACT during RFA (r=0.25; P<0.001; Figure 1A -1C, respectively). There was a negative correlation between the INR and the total heparin dose adjusted for body weight during the RFA procedure (r=0.61; P<0.001; Figure 1D ). The mean baseline ACT was 153±31 seconds in patients with INRs<2.0, 189±23 s in patients with INRs of 2 to 3, and 211±25 seconds in patients with INRs>3.0 (P<0.001 for all comparisons). The mean ACT during the procedure was 323±19 seconds, when the INR was <2.0, and was significantly lower than when the INR was 2.0 to 3.0 (339±19 seconds; P<0.001) and when INR was >3.0 (342±20 seconds; P<0.001). The maximum ACT during the procedure in patients with an INR<2.0, 360±15 seconds, was also significantly lower than in patients with an INR 2 to 3, 368±19 seconds (P<0.001), and in patients with an INR>3.0, 370±18 seconds (P<0.001). The mean total heparin dosage needed to maintain a therapeutic ACT during RFA was lower in patients with an INR of 2 to 3 (133±55 U/kg) and >3.0 (103±41 U/kg) than in patients with an INR<2.0 (235±101 U/kg; P<0.001). There was no further decrease in total heparin requirements once the INR was >2 ( Table 1) .
Procedural Complications
Bleeding complications occurred in 89/1133 patients (8%) and included minor bleeding in 56 patients (5%), vascular complications in 19 patients (2%); and pericardial tamponade in 14 patients (1%, Table 2 ). Thromboembolic complications occurred in 3 patients (0.3%) after RFA, and included a transient ischemic attack in 2 patients (0.2%) and deep vein thrombosis of a lower extremity in 1 patient (0.1%). Except in 3 patients, all bleeding complications occurred during or shortly after the RFA, while the patient was monitored as an inpatient. A delayed groin hematoma developed in 3 patients 4.0±2.6 days after the RFA and prompted a readmission. All of these patients were receiving LMWH for an INR<2.0. Hematoma resolved without intervention in these 3 patients.
A transient ischemic attack occurred in 2 patients within few hours after the RFA and completely resolved within 6 to 12 hours. Both of these patients had persistent AF, and there was no evidence of intracardiac thrombus on transesophageal echocardiogram before the procedure. Their CHA 2 DS 2 -VASc scores were 2 and 1. At the time of transient ischemic attack, they both were in sinus rhythm and had an INR of 1.1 and 1.5. They were receiving heparin. On neurological imaging (computed tomography and MRI), there was no evidence of an intracerebral thromboembolic event.
One patient had an acute deep vein thrombosis in right ileofemoral vein just after the procedure, and the patient was in sinus rhythm. His CHA 2 DS 2 -VASc score was 2, and INR was 1.3. This patient received an inferior vena cava filter and heparin bridging to warfarin. All patients with thromboembolic complications had an INR<2.0. Among the 1133 patients, only 1 experienced >1 complication, an arteriovenous fistula, and a deep vein thrombosis. There were no other complications.
INR and Complications
Patients with an INR<1.5 had more bleeding complications than patients with an INR≥2.0 and <2.5 (12% versus 4%; P<0.001; Figure 3 ). Patients with an INR<1.5 also had more vascular complications and groin hematomas than patients with an INR>2 and <2.5 (3% versus 1%, P=0.02; and 8% versus 3%, P=0.006, respectively). The prevalence of total bleeding complications was not significantly different in patients with INRs of 2.0 to 3.5 (Figure 2) , however significantly increased in patients with an INR>3.5 (31%) compared with patients with lower INRs of ≥2.0 and <2.5 (4%; P=0.003), ≥2.5 and <3.0 (8%; P=0.02) and ≥3.0 and <3.5 (8%; P=0.04; Figure 2 ).
Procedural ACT Levels, Heparin Requirements, and Complications
The baseline ACT did not correlate with major or minor bleeding complications. The mean and maximum ACT during the procedure had a positive correlation with pericardial tamponade (r=0.09, P=0.004; and r=0.09, P=0.002, respectively). There was a direct relationship between the total heparin requirements and vascular complications (r=0.06; P=0.04) and groin hematomas (r=0.08; P=0.01). On multivariate analysis, however, there was no association between ACT levels or heparin requirements and bleeding or vascular complications. In patients with an INR<2.0, the prevalence of bleeding complications was 35/433 (8%) when heparin was used, 28/373 (8%) when LMWH was used, and 3/12 (25%) when clopidogrel was used.
The INR and Risk of Complications
Because the distribution of bleeding complications based on INR was U-shaped, a quadratic logistic regression model was used to analyze the relationship between the bleeding complications and INR. Although clopidogrel use had a weak correlation with INR (r=0.06; P=0.04), with both total bleeding complications (r=0.08; P=0.006) and groin hematomas (r=0.09; P=0.004), clopidogrel use was a significant explanatory variable for the quadratic INR function determined by the variable selection procedure (P=0.01). Therefore, logistic regression analysis was adjusted according to clopidogrel use. There were no other clinical predictors of complications.
On logistic regression analysis of the INR versus bleeding complications, the quadratic model had a better goodness-of-fit (Akaike Information Criterion=606; P<0.001; Figure 3 ) than the null (Akaike Information Criterion=622) and linear models (Akaike Information Criterion=622). There was no relationship between pericardial tamponade and INR either by the linear or quadratic models. There was a significant relationship between the INR and vascular complications (P=0.03) and groin hematomas (P<0.001).
Clopidogrel use was associated with a higher probability of developing overall bleeding complications (odds ratio=3.1; ±95% CI, 1.4-7.4; P=0.006) and groin hematomas (odds ratio=3.7; ±95% CI, 1.4-9.4; P=0.007), but not with pericardial tamponade (P=0.4) or vascular complications (P=0.6).
From the x-coordinate of vertex (angular point; -β/2γ) in the quadratic equation and its 95% CI, optimal range of INR associated with the lowest risk of an adverse event was estimated as 2.3 (95% CI, 2.1-2.5) for total bleeding complications, 2.5 (95% CI, 0.6-5.4) for vascular complications, and 2.2 (95% CI, 2.0-2.5) for groin hematomas (Figure 3 and Table 3 ). Table 3 ) is 2.3 with 95% confidence intervals of 2.1 and 2.5.
Discussion
Main Findings
The main findings of this study are the following: (1) there is a quadratic relationship between the preprocedural INR and the risk of hemorrhagic or thromboembolic complications during RFA of AF; (2) the risk of bleeding and thromboembolic complications is higher when the INR is subtherapeutic (<2), and the risk of bleeding complications is higher when the INR is >3, with a further steep increase in risk at INRs>3.5; (3) there is no relationship between the INR and risk of pericardial tamponade; (4) intraprocedural heparin requirements to maintain an ACT between 300 and 350 seconds are reduced by 50% when the INR is >2. However, when the INR is >2, there is no relationship between INR and heparin requirements; (5) there is a weak but significant direct relationship between the ACT during RFA and the risk of pericardial tamponade; and (6) concomitant clopidogrel use seems to be associated with a 3-fold increase in bleeding complications.
Procedural INRs, Heparin Requirements, and ACT Levels
The optimal range of INRs for RFA of AF has not been described. INR levels often vary before a scheduled procedure because of changes in diet, travel, and NPO status. Therefore, the INR may be outside of the typical 2 to 3 range immediately before the procedure. In this study, INR was within the range of 2 to 3 in only 50% of patients. 5 Despite therapeutic anticoagulation with warfarin, it has been recommended to maintain the ACT at >300 seconds during RFA of AF. 6 In patients with an INR of 1, unfractionated heparin at initial doses of 100-120 U/kg usually is required to achieve such ACT levels with subsequent intermittent boluses or continuous infusion during RFA. A previous study demonstrated that baseline ACT levels were higher in patients with an INR≥2 than in patients with an INR<2. 7 In this study, baseline ACT levels were elevated by ≈25% and ≈40% in patients with INRs>2 and >3, respectively. Total intraprocedural heparin dose was reduced by ≈50%. However, there was no further decrease in heparin requirements at INRs>2.0.
Warfarin and heparin interfere with different components of the coagulation cascade. Warfarin has a facilitatory role on the anticoagulant effects of heparin, 8 which is likely to become saturated at INRs>2. The findings of this study suggest that unfractionated heparin should be administered at half of the regular dose, that is, 50 to 60 U/kg in patients with an INR>2. This is likely to prevent overshooting of the target ACT range, which was shown to correlate with the risk of pericardial tamponade in this study. The optimal dose of heparin during RFA in patients with a therapeutic INR remains to be determined.
Complications
The prevalence of major and minor complications was 8% in this study, and included minor bleeding in 5%, vascular complications in 2%, pericardial tamponade in 1%, and thromboembolic events in 0.3%. The prevalence of bleeding and vascular complications has been reported previously to vary between 0.8% and 13%. 1, 2, [9] [10] [11] In a worldwide survey of RFA for AF, major complications including arteriovenous fistula and pseudoaneurysm, and pericardial tamponade were reported in 1.5% and 1.3% of the patients, respectively. 4 A number of variables such as the rigor with which complications, particularly the minor ones, are recorded, the technique and technology used for vascular access and RFA, anticoagulation regimen, patient characteristics, operator experience, and RFA settings can each affect the risk of complications.
In this study, a U-shaped relationship between INR and bleeding complications was observed. INRs<2 and >3 were associated with a ≈2 fold increase in the risk of bleeding complications. In patients with a subtherapeutic INR, total heparin requirements during RFA and the need for LMWH after the procedure are greater than in patients who have a therapeutic INR. Previous studies have demonstrated that uninterrupted anticoagulation with warfarin at INRs>2 is associated with fewer bleeding complications compared with interrupted warfarin. [1] [2] [3] 7 In this study, there was a direct relationship between the total dose of heparin and the risk of complications. LMWH has been recognized to increase the risk of vascular and bleeding complications, even at reduced doses. 3, 7, 12 Large doses of heparin and LMWH lead to wide variations in anticoagulant activity and lead to an increase in the risk of bleeding complications, particularly groin hematomas and vascular complications. On the other hand, a consistent and therapeutic anticoagulant milieu during RFA can be achieved with uninterrupted anticoagulation using warfarin and lower doses of heparin. 7, 13 Therefore, use of heparin products, particularly LMWH as a bridge to therapeutic anticoagulation with warfarin in patients who present with a subtherapeutic INR before the procedure, is likely to increase the risk of bleeding complications and should be minimized whenever possible.
A new finding of this study is that the risk of bleeding complications increased by 2-fold in patients who had an INR>3, with a further 6-fold increase when the INR exceeded 3.5. Patients who had an INR>3 or >3.5 received lower total doses of heparin. Therefore, the increase in bleeding complications during or shortly after the procedure at INRs>3 most likely is attributable to the incremental anticoagulant effects of warfarin, further augmented by a synergistic effect of heparin.
Clopidogrel use was an independent predictor of bleeding complications and was associated with a significant 3-fold increase in the risk of bleeding complications at all INRs. An association between the clopidogrel use and the risk of bleeding complications after RFA, independent of concomitant warfarin use, was reported previously. 11 Therefore, although the number of patients on clopidogrel in this study was small, it seems to be advisable to discontinue clopidogrel before RFA whenever possible.
Pericardial Tamponade, INR, and ACT Levels
The prevalence of pericardial tamponade during RFA of AF seems to be independent of the anticoagulation regimen, suggesting that mechanical or radiofrequency-energyrelated perforation is the key factor. 1, 3, 7 A recent study demonstrated that outcomes of patients who had pericardial tamponade during RFA were similar regardless of the intensity of anticoagulation. 14 In this study, there was no relationship between the INR and pericardial tamponade. Because the procedure was terminated prematurely, the total heparin dosage was lower in patients who had pericardial tamponade than those who did not. On the other hand, there was a direct correlation between the risk of pericardial tamponade and both the mean and maximum ACT during RFA. Therefore, it is plausible that in patients with a therapeutic INR, high ACT levels may facilitate progression of a small puncture to tamponade. Although ACT levels ≥400 seconds are targeted at some centers, it is possible that this increases the risk of tamponade.
Study Limitations
A limitation of this retrospective analysis is the small number of patients who had INR values >3.5. However, this did not negate the ability to detect a strong association with an increased risk of bleeding complications.
Clinical Implications
The optimal INR during uninterrupted therapy with warfarin for RFA of AF falls into a rather narrow range of 2.1 to 2.5. To minimize the risk of bleeding complications, it may be helpful to start monitoring INR earlier and more frequently before the procedure to achieve steady-state, stable INR values within the desired range. High ACT levels (>350 seconds) during RFA may be associated with a higher risk of pericardial tamponade. Total heparin dose should be reduced by 50% in patients with an INR >2. Concomitant clopidogrel use with warfarin seems to be associated with almost a 3-fold increase in the risk of bleeding complications and should be avoided when possible. Whether the use of new anticoagulants, such as dabigatran or rivaroxaban, will prove to be safer than uninterrupted warfarin during RFA of AF remains to be determined.
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